{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:52:42Z","timestamp":1775267562025,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1016\/j.ejca.2003.08.027","type":"journal-article","created":{"date-parts":[[2003,11,7]],"date-time":"2003-11-07T09:21:42Z","timestamp":1068196902000},"page":"56-63","source":"Crossref","is-referenced-by-count":95,"title":["HER2\/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?"],"prefix":"10.1016","volume":"40","author":[{"given":"Z","family":"Latif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.D","family":"Watters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Grigor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.S","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2003.08.027_BIB1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0022-5347(17)38368-4","article-title":"The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial","volume":"145","author":"Skinner","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2003.08.027_BIB2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1078-1439(00)00079-X","article-title":"Genetic alterations and biological pathways in Human bladder cancer pathogenesis","volume":"5","author":"Reznikoff","year":"2000","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejca.2003.08.027_BIB3","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/bjc.1998.365","article-title":"Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?","volume":"77","author":"Bartlett","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2003.08.027_BIB4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1442-2042.1998.tb00358.x","article-title":"Numeric aberration of chromosome 17 is strongly correlated with p53 overexpression, tumor proliferation and histopathology in human bladder cancer","volume":"5","author":"Li","year":"1998","journal-title":"Int J Urol."},{"key":"10.1016\/j.ejca.2003.08.027_BIB5","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.ejca.2003.08.027_BIB6","unstructured":"Sliwkowski, M. X., Lofgren, J. A., Lewis, G. D., Hotaling, T. E., Fendly, B. M. and Fox, J. A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol, 26(Suppl. 12), 60\u201370."},{"key":"10.1016\/j.ejca.2003.08.027_BIB7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-5347(01)66653-9","article-title":"C-erbB-2 in bladder cancer molecular biology, correlation with epidermal growth factor receptors and prognostic value","volume":"155","author":"Mellon","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2003.08.027_BIB8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0090-4295(99)00604-4","article-title":"C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer","volume":"55","author":"Miyamoto","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.ejca.2003.08.027_BIB9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-5347(17)38356-8","article-title":"Expression of c-erbB-2 gene product in urinary bladder cancer","volume":"145","author":"Moriyama","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2003.08.027_BIB10","first-page":"2199","article-title":"Heterogeneity of erbB-2 gene amplification in bladder cancer","volume":"53","author":"Sauter","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.08.027_BIB11","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/1097-0142(19921115)70:10<2493::AID-CNCR2820701017>3.0.CO;2-K","article-title":"An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma","volume":"70","author":"Sato","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2003.08.027_BIB12","first-page":"2422","article-title":"C-erbB-2 gene amplification","volume":"55","author":"Underwood","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.08.027_BIB13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/jcp.53.12.890","article-title":"Recommendations for HER2 testing in the UK","volume":"53","author":"Ellis","year":"2000","journal-title":"J Clin. Path"},{"key":"10.1016\/j.ejca.2003.08.027_BIB14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejca.2003.08.027_BIB15","doi-asserted-by":"crossref","unstructured":"Baselga J. Clinical trials of Herceptin. Eur J Cancer 2001, s18\u2013s24.","DOI":"10.1016\/S0959-8049(00)00404-4"},{"key":"10.1016\/j.ejca.2003.08.027_BIB16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1464-410x.2000.00326.x","article-title":"Aneusomy of chromosomes 7 and 17 predicts recurrence in TCC of the urinary bladder","volume":"85","author":"Watters","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2003.08.027_BIB17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1464-410x.1999.00268.x","article-title":"Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy","volume":"84","author":"Bartlett","year":"1999","journal-title":"Br J Urol Int"},{"key":"10.1016\/j.ejca.2003.08.027_BIB18","first-page":"23","article-title":"Detection of numerical aberration in chromosome 17 and c-erbB2 gene amplification in epithelial ovarian cancer using a recently established dual colour FISH","volume":"22","author":"Fukushi","year":"2001","journal-title":"Eur J Gynaec Oncol"},{"key":"10.1016\/j.ejca.2003.08.027_BIB19","first-page":"2403","article-title":"Over-expression of HER2 in ovarian carcinomas","volume":"61","author":"Hellstrom","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.08.027_BIB20","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/cncr.10526","article-title":"HER2\/neu is over-expressed infrequently in patients with prostate carcinoma","volume":"94","author":"Lara","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2003.08.027_BIB21","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","article-title":"HER2 expression and progression toward androgen independence in human prostate cancer","volume":"92","author":"Signoretti","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.ejca.2003.08.027_BIB22","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1038\/bjc.1995.146","article-title":"Targeting gene transcription","volume":"71","author":"Hollywood","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2003.08.027_BIB23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/emm.2001.3","article-title":"Post-transcriptional control of c-erb B2 overexpression in stoamch cancer cells","volume":"33","author":"Bae","year":"2001","journal-title":"Exp Mol Med."},{"key":"10.1016\/j.ejca.2003.08.027_BIB24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0959-8049(00)00401-9","article-title":"Closing remarks and treatment guidelines","volume":"37","author":"Piccart","year":"2001","journal-title":"Eur. J. Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804903007913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804903007913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T03:52:15Z","timestamp":1550375535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804903007913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0959804903007913"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2003.08.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}